Circadian to invest in memory, brain research
11 April, 2002 by Tanya HollisCircadian Technologies will invest almost $450,000 over the next 18 months in two new projects, the development company announced today.
Peptech expects to cash in on Abbott drug approval
11 April, 2002 by Daniella GoldbergA rheumatoid arthritis treatment developed by Sydney biotech Peptech could become the first of its monoclonal antibodies to hit the market, if drug giant Abbott Laboratories wins approval to market the drug Adalimumab in the US and Europe.
Prima creates new R&D role
10 April, 2002 by Tanya HollisPrima Biomed (ASX:PRR) today announced it had created a new research and development position to support its commercialisation abilities.
Cytopia teams with cancer research heavy-hitters
09 April, 2002 by Melissa TrudingerMelbourne company Cytopia has teamed with the Ludwig Institute for Cancer Research in Melbourne, the Queensland Institute of Medical Research (QIMR), and New York's Sloan-Kettering Institute for Cancer Research to develop new lead drug compounds for treatment of metastatic cancers based on the Eph receptor protein.
Norwood seeks microneedle partners
09 April, 2002 by Tanya HollisDrug development and delivery company Norwood Abbey (ASX: NAL) is seeking partners to further progress its prototype microneedle.
New GM cotton licenses approved
09 April, 2002 by Melissa TrudingerThe Office of the Gene Technology Regulator (OGTR) has approved three new licenses to conduct field trials of genetically modified (GM) cotton.
Agenix antibody manufacture trial successful
09 April, 2002 by Melissa TrudingerBrisbane-based company Agenix has successfully manufactured 1.4g of its clot-binding humanised antibody under good laboratory practice (GLP) conditions in preparation for pre-clinical testing of its Thromboview blood clot imaging system, the company said.
Nature backs away from Mexico transgenic study
08 April, 2002 by Melissa TrudingerPrestigious scientific journal Nature has been forced to back away from its support of a controversial study claiming that transgenic DNA sequences from GM corn contaminated native maize in Mexico.
Progen cancer trial extended
08 April, 2002 by Tanya HollisTests of an Australian cancer drug intended to block angiogenesis have progressed with the announcement of a third patient commencing treatment under the phase II study.
Genetic Technologies in licensing deal with Sequenom
08 April, 2002 by Melissa TrudingerMelbourne based biotech company Genetic Technologies (ASX:GTG) expects to turn a profit this year after securing its first license agreement with a US-based company for use of GTG's non-coding patents for genomic mapping and intron sequence analysis.
Acrux teams with Pharmacia to explore transdermal tech
08 April, 2002 by Melissa TrudingerMelbourne start-up company Acrux has signed an agreement with pharmaceutical giant Pharmacia to explore the use of Acrux's proprietary transdermal drug delivery technology for Pharmacia's drugs.
Prana moves forward on Alzheimer's treatment
05 April, 2002 by Melissa TrudingerA treatment for Alzheimer's Disease is one step closer after the successful completion of a Phase II clinical trial by Prana Biotechnology for its drug PBT-1 (Iodochlorhydroxyquin).
Gene tech test for soil heath
05 April, 2002 by Melissa TrudingerScientists at CSIRO are developing a method for using genetic technologies to determine the health of soil.
Salinity solution sought
05 April, 2002 by Daniella GoldbergThe salinity problem plaguing farmers in the Murray-Darling Basin and other dry land regions around Australia is not going to improve unless private investors help out, according to experts who will meet in NSW state Parliament on Monday April 8.
Rice sequence sparks controversy
05 April, 2002 by Melissa TrudingerRice's genome has been sequenced and is the first complete cereal plant sequence to be publicly released.
